Castration-Resistant Prostate Cancer (CRPC) Treatment Market

Q: What is North America's expected share in 2023?

North America is likely to generate 46% revenue in 2023. Read Report

Q: What is the Projected Size of the Market by 2033?

The global market size to reach US$ 28 billion by 2033. Read Report

Castration-Resistant Prostate Cancer (CRPC) Treatment Market Snapshot (2023 to 2033)

The global castration-resistant prostate cancer (CRPC) treatment market is expected to garner a market value of US$ 11.3 Billion in 2023 and is expected to accumulate a market value of US$ 28 Billion by registering a CAGR of 9.5% in the forecast period 2023 to 2033. Growth of the castration-resistant prostate cancer (CRPC) treatment market can be attributed to increasing prevalence of the ailment and use of combination therapies to treat the ailment. The market for castration-resistant prostate cancer (CRPC) treatment registered a CAGR of 6% in the historical period 2018 to 2022

Castration-resistant prostate cancer (CRPC) is a form of advanced prostate cancer that has become resistant to traditional hormone therapy (also known as androgen deprivation therapy or ADT). In CRPC, the cancer continues to grow despite low levels of testosterone in the body, which is typically the result of surgical or medical castration.

Report Attribute	Details
Expected Market Value (2023)	US$ 11.3 Billion
Anticipated Forecast Value (2033)	US$ 28 Billion
Projected Growth Rate (2023 to 2033)	9.5% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Castration-Resistant Prostate Cancer (CRPC) Treatment Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights- the market for Castration-Resistant Prostate Cancer (CRPC) Treatment reflected a value of 6% during the historical period, 2018 to 2022.

Increasing prevalence of prostate cancer, the development of new therapies, and the rising demand for personalized medicine is driving the growth of the castration-resistant prostate cancer (CRPC) treatment market. Moreover, research and development along with technological integration for innovating medication is expected to bolster the demand for treatment of castration-resistant prostate cancer (CRPC) treatment market.

Thus, the market for Castration-Resistant Prostate Cancer (CRPC) Treatment is expected to register a CAGR of 9.5% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of Castration-Resistant Prostate Cancer (CRPC) Treatment Market?

Availability of diagnostic tools shaping landscape for CRPC market

The increasing incidence of prostate cancer, which is one of the most common cancers among men, is driving the demand for effective treatments for CRPC. The development of new treatment options, including targeted therapies, immunotherapies, and radiopharmaceuticals, has expanded the range of options available for the treatment of CRPC.

The aging population is more susceptible to prostate cancer and CRPC, and this demographic trend is increasing the demand for effective treatments for this disease. The availability of diagnostic tools such as imaging technologies, genomic testing, and liquid biopsies has improved the detection and monitoring of CRPC, which is contributing to the demand for effective treatments.

The increasing research and development activities in the field of oncology, including prostate cancer, are leading to the development of new and innovative treatments for CRPC. The government initiatives aimed at increasing awareness of prostate cancer and improving access to healthcare services are contributing to the growth of the CRPC treatment market.

Presence of different treatments creative lucrative opportunities for CRPC market

Second-line hormone therapy: This involves the use of different types of hormone therapy drugs that target different aspects of the androgen receptor pathway.

Chemotherapy: Chemotherapy drugs such as docetaxel and cabazitaxel may be used to treat CRPC.

Immunotherapy: Immune checkpoint inhibitors such as pembrolizumab and nivolumab have been approved for the treatment of certain types of CRPC.

Radiopharmaceutical therapy: Radiopharmaceuticals such as radium-223 and lutetium-177 PSMA have been approved for the treatment of CRPC that has spread to the bones.

Targeted therapy: Targeted drugs such as enzalutamide, abiraterone, and apalutamide may be used to treat CRPC by blocking specific pathways that fuel the growth of cancer cells.

Clinical trials: Participation in clinical trials of new treatments is also an option for some patients with CRPC.

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the Castration-Resistant Prostate Cancer (CRPC) Treatment Market?

Limited efficiency of treatments along with expensive nature of treatment affecting market growth

Many of the available treatment options for CRPC are expensive, and this can make them inaccessible to patients who cannot afford them or are not covered by health insurance. The side effects of many CRPC treatments, such as chemotherapy and immunotherapy, can be severe and impact a patient's quality of life. This can make it challenging for patients to tolerate the treatments and continue with their treatment plans.

While there are several treatment options available for CRPC, not all of them are effective for every patient. Some patients may not respond to certain treatments, and this can limit the efficacy of the available options. Some patients may develop resistance to the available treatments, which can make it challenging to manage their disease and prolong their survival.

Despite the advances in research and development, the underlying mechanisms of CRPC are not fully understood, and this can make it challenging to develop new and more effective treatments. Developing new treatments for CRPC can be challenging due to regulatory requirements, including the need for extensive clinical trials to demonstrate safety and efficacy. All these factors are derailing the growth of CRPC market.

Region-Wise Insights

Advanced Healthcare Infrastructure Boosting Market Growth of CRPC in North America?

Newer targeted therapies creating lucrative opportunities for CPRC treatment

The North American market for Castration-Resistant Prostate Cancer (CRPC) treatment is one of the largest markets in the world, due to the high prevalence of prostate cancer in the region and the availability of advanced healthcare infrastructure.

In terms of treatment options, chemotherapy and hormone therapy have been the mainstays of CRPC treatment in North America for many years, but newer targeted therapies such as abiraterone, enzalutamide, apalutamide, and radium-223 have also been approved for use. Immunotherapy, such as the use of immune checkpoint inhibitors, is also being investigated for CRPC treatment. Thus, North America is expected to possess 46% market share for castration-resistant prostate cancer (CRPC) treatment market in 2023.

Introduction of Novel Treatments Supporting Growth of CRPC Treatment Market in Europe?

Increasing awareness of diagnosis propelling demand for CRPC treatment in Europe

The Europe CRPC treatment market is being driven by the increasing prevalence of the disease in the region, as well as the growing awareness and diagnosis of the disease. In addition, the market is being driven by the introduction of novel treatments that offer better efficacy and fewer side effects than traditional therapies.

One of the most promising developments in CRPC treatment is the use of targeted therapies. These drugs are designed to specifically target the cancer cells and limit their growth and spread, while minimizing damage to healthy cells. Targeted therapies such as enzalutamide and abiraterone have shown significant benefits in treating CRPC, leading to their approval by regulatory agencies in Europe. Thus, Europe is expected to possess 40% market share for castration-resistant prostate cancer (CRPC) treatment market in 2023.

Category-Wise Insights

Ease and Accessibility of Consuming Oral Medications Making Them Popular for CRPC Treatment?

Ease to administer oral medication increasing dependency to treat CRPC treatment

The oral route offers patients the convenience of taking medication in the comfort of their own homes. This is particularly beneficial for CRPC patients, who may need to take medication for extended periods of time. Oral medications can be taken without the need for hospital visits or invasive procedures, making treatment more accessible and less disruptive to a patient's daily life.

In addition, the oral route of administration can help to improve patient adherence to treatment. Patients are more likely to take their medication as prescribed when it is delivered in a convenient, easy-to-administer format. This is particularly important in the treatment of CRPC, where adherence to therapy is crucial for achieving positive treatment outcomes. Thus, by drug delivery method, oral route is expected to possess 55% market share for castration-resistant prostate cancer (CRPC) treatment market in 2023.

Market Competition

Key players in the castration-resistant prostate cancer (CRPC) treatment market are Sanofi S.A., Johnson and Johnson, Pfizer, Inc., Bayer AG, Abbott Laboratories, GlaxoSmithKline PLC, Northwest Biotherapeutics, Inc., Active Biotech AB, Astellas Pharma, Inc, Dendreon Corporation

In 2018, Sanofi and Regeneron Pharmaceuticals announced the results of a phase 3 clinical trial investigating the use of their immunotherapy drug, cemiplimab, in combination with Jevtana for the treatment of metastatic CRPC. The trial showed promising results, with the combination therapy significantly improving overall survival and progression-free survival compared to Jevtana alone.
In 2019, Pfizer announced the results of a phase 3 clinical trial investigating the use of Xtandi in combination with abiraterone acetate, another androgen receptor inhibitor, for the treatment of metastatic CRPC.

Report Scope

Report Attribute	Details
Market Value in 2023	US$ 11.3 Billion
Market Value in 2033	US$ 28 Billion
Growth Rate	CAGR of 9.5% from 2023 to 2033
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered	Therapy Type Drug Class Drug Delivery Method Distribution Channel Region
Regions Covered	North America Latin America Western Europe Eastern Europe APEJ Japan Middle East and Africa
Key Countries Profiled	USA Canada Brazil Mexico Rest of Latin America Germany United Kingdom France Spain Italy Rest of Europe India Malaysia Singapore Thailand Rest of South Asia China Japan South Korea Austria New Zealand GCC countries South Africa Israel Rest of MEA
Key Companies Profiled	Sanofi S.A. Johnson and Johnson Pfizer, Inc. Bayer AG Abbott Laboratories GlaxoSmithKline PLC Northwest Biotherapeutics, Inc. Active Biotech AB Astellas Pharma, Inc Dendreon Corporation
Customization	Available Upon Request

Key Segments Profiled in the Castration-Resistant Prostate Cancer (CRPC) Treatment Industry Survey

Therapy Type:

Hormonal therapy
Chemotherapy
Immunotherapy
Radiotherapy

Drug Class:

Antineoplastic
Non-steroidal Antiandrogen
Corticosteroids
Microtubule Inhibitor

Drug Delivery Method:

Oral Route
Injectable Route

Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
MEA

Frequently Asked Questions

Which region holds high lucrativeness in the Castration-Resistant Prostate Cancer (CRPC) Treatment Market?

The Asia Pacific region is projected to emerge as a lucrative market for Castration-Resistant Prostate Cancer (CRPC) Treatment.

What is the growth potential of the Castration-Resistant Prostate Cancer (CRPC) Treatment Market?

The growth potential of the Castration-Resistant Prostate Cancer (CRPC) Treatment market is 8% through 2033.

What limits the growth potential of the Market?

The high cost of treatment is likely to limit market growth.

What is North America's expected share in 2023?

North America is likely to generate 46% revenue in 2023.

What is the Projected Size of the Market by 2033?

The global market size to reach US$ 28 billion by 2033.

Table of Content

1. Executive Summary | Castration-Resistant Prostate Cancer (CRPC) Treatment Market

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Market Background

3.1. Market Dynamics

3.1.1. Drivers

3.1.2. Restraints

3.1.3. Opportunity

3.1.4. Trends

3.2. Scenario Forecast

3.2.1. Demand in Optimistic Scenario

3.2.2. Demand in Likely Scenario

3.2.3. Demand in Conservative Scenario

3.3. Opportunity Map Analysis

3.4. Investment Feasibility Matrix

3.5. PESTLE and Porter’s Analysis

3.6. Regulatory Landscape

3.6.1. By Key Regions

3.6.2. By Key Countries

3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

4.2.1. Y-o-Y Growth Trend Analysis

4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy Type

5.1. Introduction / Key Findings

5.2. Historical Market Size Value (US$ Million) Analysis By Therapy Type, 2018 to 2022

5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy Type, 2023 to 2033

5.3.1. Hormonal therapy

5.3.2. Chemotherapy

5.3.3. Immunotherapy

5.3.4. Radiotherapy

5.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2018 to 2022

5.5. Absolute $ Opportunity Analysis By Therapy Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

6.1. Introduction / Key Findings

6.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022

6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033

6.3.1. Antineoplastic

6.3.2. Non-steroidal Antiandrogen

6.3.3. Corticosteroids

6.3.4. Microtubule Inhibitor

6.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022

6.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Delivery Method

7.1. Introduction / Key Findings

7.2. Historical Market Size Value (US$ Million) Analysis By Drug Delivery Method , 2018 to 2022

7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Delivery Method , 2023 to 2033

7.3.1. Oral Route

7.3.2. Injectable Route

7.4. Y-o-Y Growth Trend Analysis By Drug Delivery Method , 2018 to 2022

7.5. Absolute $ Opportunity Analysis By Drug Delivery Method , 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

8.1. Introduction / Key Findings

8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

8.3.1. Hospital Pharmacies

8.3.2. Retail Pharmacies

8.3.3. Online Pharmacies

8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

9.1. Introduction

9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

9.3.1. North America

9.3.2. Latin America

9.3.3. Europe

9.3.4. South Asia

9.3.5. East Asia

9.3.6. Oceania

9.3.7. MEA

9.4. Market Attractiveness Analysis By Region

10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

10.2.1. By Country

10.2.1.1. USA

10.2.1.2. Canada

10.2.2. By Therapy Type

10.2.3. By Drug Class

10.2.4. By Drug Delivery Method

10.2.5. By Distribution Channel

10.3. Market Attractiveness Analysis

10.3.1. By Country

10.3.2. By Therapy Type

10.3.3. By Drug Class

10.3.4. By Drug Delivery Method

10.3.5. By Distribution Channel

10.4. Key Takeaways

11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

11.2.1. By Country

11.2.1.1. Brazil

11.2.1.2. Mexico

11.2.1.3. Rest of Latin America

11.2.2. By Therapy Type

11.2.3. By Drug Class

11.2.4. By Drug Delivery Method

11.2.5. By Distribution Channel

11.3. Market Attractiveness Analysis

11.3.1. By Country

11.3.2. By Therapy Type

11.3.3. By Drug Class

11.3.4. By Drug Delivery Method

11.3.5. By Distribution Channel

11.4. Key Takeaways

12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

12.2.1. By Country

12.2.1.1. Germany

12.2.1.2. United Kingdom

12.2.1.3. France

12.2.1.4. Spain

12.2.1.5. Italy

12.2.1.6. Rest of Europe

12.2.2. By Therapy Type

12.2.3. By Drug Class

12.2.4. By Drug Delivery Method

12.2.5. By Distribution Channel

12.3. Market Attractiveness Analysis

12.3.1. By Country

12.3.2. By Therapy Type

12.3.3. By Drug Class

12.3.4. By Drug Delivery Method

12.3.5. By Distribution Channel

12.4. Key Takeaways

13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

13.2.1. By Country

13.2.1.1. India

13.2.1.2. Malaysia

13.2.1.3. Singapore

13.2.1.4. Thailand

13.2.1.5. Rest of South Asia

13.2.2. By Therapy Type

13.2.3. By Drug Class

13.2.4. By Drug Delivery Method

13.2.5. By Distribution Channel

13.3. Market Attractiveness Analysis

13.3.1. By Country

13.3.2. By Therapy Type

13.3.3. By Drug Class

13.3.4. By Drug Delivery Method

13.3.5. By Distribution Channel

13.4. Key Takeaways

14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

14.2.1. By Country

14.2.1.1. China

14.2.1.2. Japan

14.2.1.3. South Korea

14.2.2. By Therapy Type

14.2.3. By Drug Class

14.2.4. By Drug Delivery Method

14.2.5. By Distribution Channel

14.3. Market Attractiveness Analysis

14.3.1. By Country

14.3.2. By Therapy Type

14.3.3. By Drug Class

14.3.4. By Drug Delivery Method

14.3.5. By Distribution Channel

14.4. Key Takeaways

15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

15.2.1. By Country

15.2.1.1. Australia

15.2.1.2. New Zealand

15.2.2. By Therapy Type

15.2.3. By Drug Class

15.2.4. By Drug Delivery Method

15.2.5. By Distribution Channel

15.3. Market Attractiveness Analysis

15.3.1. By Country

15.3.2. By Therapy Type

15.3.3. By Drug Class

15.3.4. By Drug Delivery Method

15.3.5. By Distribution Channel

15.4. Key Takeaways

16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

16.2.1. By Country

16.2.1.1. GCC Countries

16.2.1.2. South Africa

16.2.1.3. Israel

16.2.1.4. Rest of MEA

16.2.2. By Therapy Type

16.2.3. By Drug Class

16.2.4. By Drug Delivery Method

16.2.5. By Distribution Channel

16.3. Market Attractiveness Analysis

16.3.1. By Country

16.3.2. By Therapy Type

16.3.3. By Drug Class

16.3.4. By Drug Delivery Method

16.3.5. By Distribution Channel

16.4. Key Takeaways

17. Key Countries Market Analysis

17.1. USA

17.1.1. Pricing Analysis

17.1.2. Market Share Analysis, 2022

17.1.2.1. By Therapy Type

17.1.2.2. By Drug Class

17.1.2.3. By Drug Delivery Method

17.1.2.4. By Distribution Channel

17.2. Canada

17.2.1. Pricing Analysis

17.2.2. Market Share Analysis, 2022

17.2.2.1. By Therapy Type

17.2.2.2. By Drug Class

17.2.2.3. By Drug Delivery Method

17.2.2.4. By Distribution Channel

17.3. Brazil

17.3.1. Pricing Analysis

17.3.2. Market Share Analysis, 2022

17.3.2.1. By Therapy Type

17.3.2.2. By Drug Class

17.3.2.3. By Drug Delivery Method

17.3.2.4. By Distribution Channel

17.4. Mexico

17.4.1. Pricing Analysis

17.4.2. Market Share Analysis, 2022

17.4.2.1. By Therapy Type

17.4.2.2. By Drug Class

17.4.2.3. By Drug Delivery Method

17.4.2.4. By Distribution Channel

17.5. Germany

17.5.1. Pricing Analysis

17.5.2. Market Share Analysis, 2022

17.5.2.1. By Therapy Type

17.5.2.2. By Drug Class

17.5.2.3. By Drug Delivery Method

17.5.2.4. By Distribution Channel

17.6. United Kingdom

17.6.1. Pricing Analysis

17.6.2. Market Share Analysis, 2022

17.6.2.1. By Therapy Type

17.6.2.2. By Drug Class

17.6.2.3. By Drug Delivery Method

17.6.2.4. By Distribution Channel

17.7. France

17.7.1. Pricing Analysis

17.7.2. Market Share Analysis, 2022

17.7.2.1. By Therapy Type

17.7.2.2. By Drug Class

17.7.2.3. By Drug Delivery Method

17.7.2.4. By Distribution Channel

17.8. Spain

17.8.1. Pricing Analysis

17.8.2. Market Share Analysis, 2022

17.8.2.1. By Therapy Type

17.8.2.2. By Drug Class

17.8.2.3. By Drug Delivery Method

17.8.2.4. By Distribution Channel

17.9. Italy

17.9.1. Pricing Analysis

17.9.2. Market Share Analysis, 2022

17.9.2.1. By Therapy Type

17.9.2.2. By Drug Class

17.9.2.3. By Drug Delivery Method

17.9.2.4. By Distribution Channel

17.10. India

17.10.1. Pricing Analysis

17.10.2. Market Share Analysis, 2022

17.10.2.1. By Therapy Type

17.10.2.2. By Drug Class

17.10.2.3. By Drug Delivery Method

17.10.2.4. By Distribution Channel

17.11. Malaysia

17.11.1. Pricing Analysis

17.11.2. Market Share Analysis, 2022

17.11.2.1. By Therapy Type

17.11.2.2. By Drug Class

17.11.2.3. By Drug Delivery Method

17.11.2.4. By Distribution Channel

17.12. Singapore

17.12.1. Pricing Analysis

17.12.2. Market Share Analysis, 2022

17.12.2.1. By Therapy Type

17.12.2.2. By Drug Class

17.12.2.3. By Drug Delivery Method

17.12.2.4. By Distribution Channel

17.13. Thailand

17.13.1. Pricing Analysis

17.13.2. Market Share Analysis, 2022

17.13.2.1. By Therapy Type

17.13.2.2. By Drug Class

17.13.2.3. By Drug Delivery Method

17.13.2.4. By Distribution Channel

17.14. China

17.14.1. Pricing Analysis

17.14.2. Market Share Analysis, 2022

17.14.2.1. By Therapy Type

17.14.2.2. By Drug Class

17.14.2.3. By Drug Delivery Method

17.14.2.4. By Distribution Channel

17.15. Japan

17.15.1. Pricing Analysis

17.15.2. Market Share Analysis, 2022

17.15.2.1. By Therapy Type

17.15.2.2. By Drug Class

17.15.2.3. By Drug Delivery Method

17.15.2.4. By Distribution Channel

17.16. South Korea

17.16.1. Pricing Analysis

17.16.2. Market Share Analysis, 2022

17.16.2.1. By Therapy Type

17.16.2.2. By Drug Class

17.16.2.3. By Drug Delivery Method

17.16.2.4. By Distribution Channel

17.17. Australia

17.17.1. Pricing Analysis

17.17.2. Market Share Analysis, 2022

17.17.2.1. By Therapy Type

17.17.2.2. By Drug Class

17.17.2.3. By Drug Delivery Method

17.17.2.4. By Distribution Channel

17.18. New Zealand

17.18.1. Pricing Analysis

17.18.2. Market Share Analysis, 2022

17.18.2.1. By Therapy Type

17.18.2.2. By Drug Class

17.18.2.3. By Drug Delivery Method

17.18.2.4. By Distribution Channel

17.19. GCC Countries

17.19.1. Pricing Analysis

17.19.2. Market Share Analysis, 2022

17.19.2.1. By Therapy Type

17.19.2.2. By Drug Class

17.19.2.3. By Drug Delivery Method

17.19.2.4. By Distribution Channel

17.20. South Africa

17.20.1. Pricing Analysis

17.20.2. Market Share Analysis, 2022

17.20.2.1. By Therapy Type

17.20.2.2. By Drug Class

17.20.2.3. By Drug Delivery Method

17.20.2.4. By Distribution Channel

17.21. Israel

17.21.1. Pricing Analysis

17.21.2. Market Share Analysis, 2022

17.21.2.1. By Therapy Type

17.21.2.2. By Drug Class

17.21.2.3. By Drug Delivery Method

17.21.2.4. By Distribution Channel

18. Market Structure Analysis

18.1. Competition Dashboard

18.2. Competition Benchmarking

18.3. Market Share Analysis of Top Players

18.3.1. By Regional

18.3.2. By Therapy Type

18.3.3. By Drug Class

18.3.4. By Drug Delivery Method

18.3.5. By Distribution Channel

19. Competition Analysis

19.1. Competition Deep Dive

19.1.1. Sanofi S.A.

19.1.1.1. Overview

19.1.1.2. Product Portfolio

19.1.1.3. Profitability by Market Segments

19.1.1.4. Sales Footprint

19.1.1.5. Strategy Overview

19.1.1.5.1. Marketing Strategy

19.1.2. Johnson and Johnson

19.1.2.1. Overview

19.1.2.2. Product Portfolio

19.1.2.3. Profitability by Market Segments

19.1.2.4. Sales Footprint

19.1.2.5. Strategy Overview

19.1.2.5.1. Marketing Strategy

19.1.3. Pfizer, Inc.

19.1.3.1. Overview

19.1.3.2. Product Portfolio

19.1.3.3. Profitability by Market Segments

19.1.3.4. Sales Footprint

19.1.3.5. Strategy Overview

19.1.3.5.1. Marketing Strategy

19.1.4. Bayer AG

19.1.4.1. Overview

19.1.4.2. Product Portfolio

19.1.4.3. Profitability by Market Segments

19.1.4.4. Sales Footprint

19.1.4.5. Strategy Overview

19.1.4.5.1. Marketing Strategy

19.1.5. Abbott Laboratories

19.1.5.1. Overview

19.1.5.2. Product Portfolio

19.1.5.3. Profitability by Market Segments

19.1.5.4. Sales Footprint

19.1.5.5. Strategy Overview

19.1.5.5.1. Marketing Strategy

19.1.6. GlaxoSmithKline PLC

19.1.6.1. Overview

19.1.6.2. Product Portfolio

19.1.6.3. Profitability by Market Segments

19.1.6.4. Sales Footprint

19.1.6.5. Strategy Overview

19.1.6.5.1. Marketing Strategy

19.1.7. Northwest Biotherapeutics, Inc.

19.1.7.1. Overview

19.1.7.2. Product Portfolio

19.1.7.3. Profitability by Market Segments

19.1.7.4. Sales Footprint

19.1.7.5. Strategy Overview

19.1.7.5.1. Marketing Strategy

19.1.8. Active Biotech AB

19.1.8.1. Overview

19.1.8.2. Product Portfolio

19.1.8.3. Profitability by Market Segments

19.1.8.4. Sales Footprint

19.1.8.5. Strategy Overview

19.1.8.5.1. Marketing Strategy

19.1.9. Astellas Pharma, Inc.

19.1.9.1. Overview

19.1.9.2. Product Portfolio

19.1.9.3. Profitability by Market Segments

19.1.9.4. Sales Footprint

19.1.9.5. Strategy Overview

19.1.9.5.1. Marketing Strategy

19.1.10. Dendreon Corporation

19.1.10.1. Overview

19.1.10.2. Product Portfolio

19.1.10.3. Profitability by Market Segments

19.1.10.4. Sales Footprint

19.1.10.5. Strategy Overview

19.1.10.5.1. Marketing Strategy

20. Assumptions & Acronyms Used

21. Research Methodology